Herbert Irving Comprehensive Cancer Center
@columbiacancer.bsky.social
Updates on innovations in #cancer research, prevention, care, and education from the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center and NewYork-Presbyterian.
Pinned
2025 Annual Report
The Herbert Irving Comprehensive Cancer Center earned renewed Comprehensive Cancer Center designation from the National Cancer Institute for 2025–2030, with $27 million in funding to strengthen cancer...
pubs.cancer.columbia.edu
The 2025 issue of Pathways to a Cure is here!
See how HICCC is driving breakthroughs in cell therapy, AI precision prevention, and early-onset cancers—while expanding access to world-class care at Columbia.
Read now ⬇️
pubs.cancer.columbia.edu/reports/2025...
See how HICCC is driving breakthroughs in cell therapy, AI precision prevention, and early-onset cancers—while expanding access to world-class care at Columbia.
Read now ⬇️
pubs.cancer.columbia.edu/reports/2025...
Sarcoma is rare, but inequities in life-saving care are widespread in underserved communities. Read how Wakenda Tyler, MD, is pushing the field to confront disparities, like higher amputation and mortality rates. #BlackHistoryMonth @columbiamed.bsky.social www.cancer.columbia.edu/news/wakenda...
Wakenda Tyler, MD: Bringing Health Equity into Sarcoma Care
In honor of Black History Month, we spoke with Dr. Tyler about why she thinks disparities research should be a priority in sarcoma care.
www.cancer.columbia.edu
February 10, 2026 at 3:48 PM
Sarcoma is rare, but inequities in life-saving care are widespread in underserved communities. Read how Wakenda Tyler, MD, is pushing the field to confront disparities, like higher amputation and mortality rates. #BlackHistoryMonth @columbiamed.bsky.social www.cancer.columbia.edu/news/wakenda...
💭 Do GLP-1s raise, lower, or not affect cancer risk?
As GLP-1 drugs surge in popularity, so have questions about their safety, especially around cancer. Based on current evidence, the answer is reassuring and increasingly hopeful. ⤵️ www.cancer.columbia.edu/news/glp-1-w...
As GLP-1 drugs surge in popularity, so have questions about their safety, especially around cancer. Based on current evidence, the answer is reassuring and increasingly hopeful. ⤵️ www.cancer.columbia.edu/news/glp-1-w...
GLP-1 Weight Loss Drugs and Cancer: Is There a Link?
GLP-1 weight-loss medications have changed how doctors treat obesity- here’s what we know about their impact on cancer.
www.cancer.columbia.edu
February 6, 2026 at 4:10 PM
💭 Do GLP-1s raise, lower, or not affect cancer risk?
As GLP-1 drugs surge in popularity, so have questions about their safety, especially around cancer. Based on current evidence, the answer is reassuring and increasingly hopeful. ⤵️ www.cancer.columbia.edu/news/glp-1-w...
As GLP-1 drugs surge in popularity, so have questions about their safety, especially around cancer. Based on current evidence, the answer is reassuring and increasingly hopeful. ⤵️ www.cancer.columbia.edu/news/glp-1-w...
A national clinical trial open at
@columbiamed.bsky.social is testing a new precision medicine approach developed by Rob Wechsler-Reya, PhD- directly testing how each patient’s tumor cells respond to different drugs, rather than testing genetics alone. →
www.cancer.columbia.edu/news/q-testi...
@columbiamed.bsky.social is testing a new precision medicine approach developed by Rob Wechsler-Reya, PhD- directly testing how each patient’s tumor cells respond to different drugs, rather than testing genetics alone. →
www.cancer.columbia.edu/news/q-testi...
Testing Drug Responses, Not Just Genes: A New Functional Precision Medicine Trial Comes to Columbia
We spoke with Rob Wechsler-Reya, PhD, about a novel functional precision medicine approach that he developed, which is being tested in a national clinical trial now opening at Columbia.
www.cancer.columbia.edu
January 30, 2026 at 7:44 PM
A national clinical trial open at
@columbiamed.bsky.social is testing a new precision medicine approach developed by Rob Wechsler-Reya, PhD- directly testing how each patient’s tumor cells respond to different drugs, rather than testing genetics alone. →
www.cancer.columbia.edu/news/q-testi...
@columbiamed.bsky.social is testing a new precision medicine approach developed by Rob Wechsler-Reya, PhD- directly testing how each patient’s tumor cells respond to different drugs, rather than testing genetics alone. →
www.cancer.columbia.edu/news/q-testi...
The 2025 issue of Pathways to a Cure is here!
See how HICCC is driving breakthroughs in cell therapy, AI precision prevention, and early-onset cancers—while expanding access to world-class care at Columbia.
Read now ⬇️
pubs.cancer.columbia.edu/reports/2025...
See how HICCC is driving breakthroughs in cell therapy, AI precision prevention, and early-onset cancers—while expanding access to world-class care at Columbia.
Read now ⬇️
pubs.cancer.columbia.edu/reports/2025...
2025 Annual Report
The Herbert Irving Comprehensive Cancer Center earned renewed Comprehensive Cancer Center designation from the National Cancer Institute for 2025–2030, with $27 million in funding to strengthen cancer...
pubs.cancer.columbia.edu
January 6, 2026 at 2:38 PM
The 2025 issue of Pathways to a Cure is here!
See how HICCC is driving breakthroughs in cell therapy, AI precision prevention, and early-onset cancers—while expanding access to world-class care at Columbia.
Read now ⬇️
pubs.cancer.columbia.edu/reports/2025...
See how HICCC is driving breakthroughs in cell therapy, AI precision prevention, and early-onset cancers—while expanding access to world-class care at Columbia.
Read now ⬇️
pubs.cancer.columbia.edu/reports/2025...
Reposted by Herbert Irving Comprehensive Cancer Center
Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma - @columbiacancer.bsky.social go.nature.com/496Ins7
Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma - Nature Biotechnology
Engineered inhalable exosomes deliver a bispecific T cell activator to pembrolizumab-resistant metastatic melanoma.
go.nature.com
January 5, 2026 at 4:09 PM
Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma - @columbiacancer.bsky.social go.nature.com/496Ins7
HICCC is presenting at #ASH2025! Follow along for highlights on research from Columbia at this year’s American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando.
↘️Be sure to tag us to be promoted!
View more: mailchi.mp/cumc/hiccc-w...
↘️Be sure to tag us to be promoted!
View more: mailchi.mp/cumc/hiccc-w...
December 5, 2025 at 8:15 PM
HICCC is presenting at #ASH2025! Follow along for highlights on research from Columbia at this year’s American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando.
↘️Be sure to tag us to be promoted!
View more: mailchi.mp/cumc/hiccc-w...
↘️Be sure to tag us to be promoted!
View more: mailchi.mp/cumc/hiccc-w...
The first FDA-approved liquid biopsy test for cancer screening is here - and raising big questions about how it could transform cancer care. HICCC’s Dr. Chin Hur weighs in. More in this Q&A 👉 cancer.columbia.edu/news/what-kn...
What to Know About Liquid Biopsies for Cancer
Liquid biopsies have the potential to transform cancer care. We asked Dr. Chin Hur how these tests fit into the future of personalized cancer screening, now that one has FDA approval.
cancer.columbia.edu
July 22, 2025 at 5:21 PM
The first FDA-approved liquid biopsy test for cancer screening is here - and raising big questions about how it could transform cancer care. HICCC’s Dr. Chin Hur weighs in. More in this Q&A 👉 cancer.columbia.edu/news/what-kn...
The Spring/Summer issue of Accelerations is here!
We're spotlighting momentum— discover what's next in cancer research, breakthroughs in drug discovery, and progress in pancreatic cancer.
Read the issue below.
hiccc-accelerations.onpubli.com/Spring-Summe...
We're spotlighting momentum— discover what's next in cancer research, breakthroughs in drug discovery, and progress in pancreatic cancer.
Read the issue below.
hiccc-accelerations.onpubli.com/Spring-Summe...
July 17, 2025 at 4:30 PM
The Spring/Summer issue of Accelerations is here!
We're spotlighting momentum— discover what's next in cancer research, breakthroughs in drug discovery, and progress in pancreatic cancer.
Read the issue below.
hiccc-accelerations.onpubli.com/Spring-Summe...
We're spotlighting momentum— discover what's next in cancer research, breakthroughs in drug discovery, and progress in pancreatic cancer.
Read the issue below.
hiccc-accelerations.onpubli.com/Spring-Summe...
Getting through the blood-brain barrier remains a huge challenge in brain tumor treatment. Read how HICCC researchers Elisa Konofagou & Stergios Zacharoulis are using #soundwaves to open it just long enough to deliver therapy.
engineering.columbia.edu/about/news/t...
engineering.columbia.edu/about/news/t...
July 9, 2025 at 7:36 PM
Getting through the blood-brain barrier remains a huge challenge in brain tumor treatment. Read how HICCC researchers Elisa Konofagou & Stergios Zacharoulis are using #soundwaves to open it just long enough to deliver therapy.
engineering.columbia.edu/about/news/t...
engineering.columbia.edu/about/news/t...
Uterine cancer is one of the few cancers with rising incidence and mortality. A new @columbiamed.bsky.social study led by HICCC’s Jason D. Wright projects a sharp increase over the next 30 years—disproportionately impacting Black women. Read more: www.cuimc.columbia.edu/news/uterine...
Uterine Cancer Rates Predicted to Rise, Especially Among Black Women
A new study forecasts a substantial rise in uterine cancer cases and deaths over the next three decades, with a disproportionate impact on Black women.
www.cuimc.columbia.edu
July 8, 2025 at 7:28 PM
Uterine cancer is one of the few cancers with rising incidence and mortality. A new @columbiamed.bsky.social study led by HICCC’s Jason D. Wright projects a sharp increase over the next 30 years—disproportionately impacting Black women. Read more: www.cuimc.columbia.edu/news/uterine...
Last week, we celebrated the official launch of the Center for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID) at Columbia. @columbiamed.bsky.social
Catch the highlights and recordings below.
@columbiaimaging.bsky.social
columbiaradiology.org/news/columbi...
Catch the highlights and recordings below.
@columbiaimaging.bsky.social
columbiaradiology.org/news/columbi...
June 25, 2025 at 5:47 PM
Last week, we celebrated the official launch of the Center for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID) at Columbia. @columbiamed.bsky.social
Catch the highlights and recordings below.
@columbiaimaging.bsky.social
columbiaradiology.org/news/columbi...
Catch the highlights and recordings below.
@columbiaimaging.bsky.social
columbiaradiology.org/news/columbi...
Reposted by Herbert Irving Comprehensive Cancer Center
Today marks Day 1 of the second cohort of the 2025 IICD Intensive Workshop. We’re thrilled to welcome a new group of graduate students and postdocs for a week of immersive learning! #CancerResearch #STEMeducation @elhamazizi.bsky.social @columbiamed.bsky.social @columbiacancer.bsky.social
June 23, 2025 at 4:08 PM
Today marks Day 1 of the second cohort of the 2025 IICD Intensive Workshop. We’re thrilled to welcome a new group of graduate students and postdocs for a week of immersive learning! #CancerResearch #STEMeducation @elhamazizi.bsky.social @columbiamed.bsky.social @columbiacancer.bsky.social
Tattoos last forever-but do they come with health risks that stick around just as long? 💭 HICCC's Dr. Mariam El-Ashmawy breaks down what early research shows —and what you can do to protect your skin with or without tattoos. www.cancer.columbia.edu/news/tattoos...
Tattoos and Skin Cancer: A Cause for Concern?
Mariam El-Ashmawy, MD, PhD, shares what you need to know about tattoos and skin cancer—and how to protect your skin for the long run.
www.cancer.columbia.edu
June 9, 2025 at 1:50 PM
Tattoos last forever-but do they come with health risks that stick around just as long? 💭 HICCC's Dr. Mariam El-Ashmawy breaks down what early research shows —and what you can do to protect your skin with or without tattoos. www.cancer.columbia.edu/news/tattoos...
Reposted by Herbert Irving Comprehensive Cancer Center
The SRP interns had a great seminar with Dr. @brentstockwell.bsky.social
Thank you, Dr. Stockwell, for sharing your career path and research with our summer interns! 🔬✨
#CancerResearch #STEMeducation #IICDSR #SummerInternship @columbiacancer.bsky.social
Thank you, Dr. Stockwell, for sharing your career path and research with our summer interns! 🔬✨
#CancerResearch #STEMeducation #IICDSR #SummerInternship @columbiacancer.bsky.social
June 4, 2025 at 2:52 PM
The SRP interns had a great seminar with Dr. @brentstockwell.bsky.social
Thank you, Dr. Stockwell, for sharing your career path and research with our summer interns! 🔬✨
#CancerResearch #STEMeducation #IICDSR #SummerInternship @columbiacancer.bsky.social
Thank you, Dr. Stockwell, for sharing your career path and research with our summer interns! 🔬✨
#CancerResearch #STEMeducation #IICDSR #SummerInternship @columbiacancer.bsky.social
Highlights from HICCC's 3rd Annual Clinical Trials Day at
@columbiamed.bsky.social 🏥👏 Thank you to everyone who joined us last week to learn about the urgent need for broader participation in #ClinicalTrials
@columbiamed.bsky.social 🏥👏 Thank you to everyone who joined us last week to learn about the urgent need for broader participation in #ClinicalTrials
June 5, 2025 at 3:58 PM
Highlights from HICCC's 3rd Annual Clinical Trials Day at
@columbiamed.bsky.social 🏥👏 Thank you to everyone who joined us last week to learn about the urgent need for broader participation in #ClinicalTrials
@columbiamed.bsky.social 🏥👏 Thank you to everyone who joined us last week to learn about the urgent need for broader participation in #ClinicalTrials
Headed to #ASCO2025 ?! 🔬✈️
Stay tuned for daily HICCC sessions, spotlight lectures, and late breaking research at @ascocancer.bsky.social !
Be sure to add our sessions to your meeting planner, and tag us to be featured! 📸 meetings.asco.org/meetings/202...
Stay tuned for daily HICCC sessions, spotlight lectures, and late breaking research at @ascocancer.bsky.social !
Be sure to add our sessions to your meeting planner, and tag us to be featured! 📸 meetings.asco.org/meetings/202...
May 29, 2025 at 5:20 PM
Headed to #ASCO2025 ?! 🔬✈️
Stay tuned for daily HICCC sessions, spotlight lectures, and late breaking research at @ascocancer.bsky.social !
Be sure to add our sessions to your meeting planner, and tag us to be featured! 📸 meetings.asco.org/meetings/202...
Stay tuned for daily HICCC sessions, spotlight lectures, and late breaking research at @ascocancer.bsky.social !
Be sure to add our sessions to your meeting planner, and tag us to be featured! 📸 meetings.asco.org/meetings/202...
Nearly everything we know about cancer started in a clinical trial. But what are clinical trials really like?
💭 🔬 Read on for answers to more common questions—and misconceptions—about cancer #clinicaltrials www.cancer.columbia.edu/news/answeri...
💭 🔬 Read on for answers to more common questions—and misconceptions—about cancer #clinicaltrials www.cancer.columbia.edu/news/answeri...
Answering 10 Commonly Asked Questions About Cancer Clinical Trials
We answer 10 of the most common—and often misunderstood—questions about how cancer clinical trials work, who they’re for, and why they matter.
www.cancer.columbia.edu
May 21, 2025 at 8:22 PM
Nearly everything we know about cancer started in a clinical trial. But what are clinical trials really like?
💭 🔬 Read on for answers to more common questions—and misconceptions—about cancer #clinicaltrials www.cancer.columbia.edu/news/answeri...
💭 🔬 Read on for answers to more common questions—and misconceptions—about cancer #clinicaltrials www.cancer.columbia.edu/news/answeri...
Cancer research is a team effort. 🌎🔬This #CancerResearchMonth the HICCC thanks everyone who makes life-changing breakthroughs possible at Columbia. @columbiamed.bsky.social
May 20, 2025 at 5:03 PM
Cancer research is a team effort. 🌎🔬This #CancerResearchMonth the HICCC thanks everyone who makes life-changing breakthroughs possible at Columbia. @columbiamed.bsky.social
Neurosurgeons at NYP / @columbiamed.bsky.social / @weillcornell.bsky.social are studying a new ultrasound tech to help drugs reach glioblastoma tumors. The SONOBIRD trial tests a device that disrupts the blood-brain barrier. More from Dr. Brian Gill below. 🧠 💊 nyp.org/advances/art...
Disrupting the Blood-Brain Barrier to Improve Glioblastoma Treatment | Spotlight | Advances in Neurology and Oncology | NewYork-Presbyterian
NewYork-Presbyterian neurosurgeon Dr. Brian Gill describes the SONOBIRD trial, which tests a new implantable ultrasound device that may improve drug delivery to the brain to treat glioblastoma.
nyp.org
May 19, 2025 at 8:21 PM
Neurosurgeons at NYP / @columbiamed.bsky.social / @weillcornell.bsky.social are studying a new ultrasound tech to help drugs reach glioblastoma tumors. The SONOBIRD trial tests a device that disrupts the blood-brain barrier. More from Dr. Brian Gill below. 🧠 💊 nyp.org/advances/art...
🗓️🥼 @columbiamed.bsky.social 2025 Clinical Trials Day brings together experts, advocates, and community leaders to explore how equity in clinical research can transform lives and strengthen communities—both locally and globally. Register below!
bit.ly/43DVFsn
bit.ly/43DVFsn
May 14, 2025 at 5:30 PM
🗓️🥼 @columbiamed.bsky.social 2025 Clinical Trials Day brings together experts, advocates, and community leaders to explore how equity in clinical research can transform lives and strengthen communities—both locally and globally. Register below!
bit.ly/43DVFsn
bit.ly/43DVFsn
👏Congratulations to HICCC Deputy Director, @drdawnhershman.bsky.social -this year’s recipient of the
@ascocancer.bsky.social Karnofsky Memorial Award!
@ascocancer.bsky.social Karnofsky Memorial Award!
May 13, 2025 at 3:56 PM
👏Congratulations to HICCC Deputy Director, @drdawnhershman.bsky.social -this year’s recipient of the
@ascocancer.bsky.social Karnofsky Memorial Award!
@ascocancer.bsky.social Karnofsky Memorial Award!